Get the Stockscreener App
0.179
0.56%
0.001
Aptose Biosciences Inc stock is traded at $0.179, with a volume of 1.04M.
It is up +0.56% in the last 24 hours and down -53.82% over the past month.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
See More
Previous Close:
$0.178
Open:
$0.19
24h Volume:
1.04M
Relative Volume:
1.45
Market Cap:
$3.48M
Revenue:
-
Net Income/Loss:
$-51.21M
P/E Ratio:
-0.0229
EPS:
-7.82
Net Cash Flow:
$-44.62M
1W Performance:
-34.46%
1M Performance:
-53.82%
6M Performance:
-83.87%
1Y Performance:
-91.94%
1-Day Range:
$0.1725
$0.19
1-Week Range:
$0.13
$0.3018
52-Week Range:
$0.13
$2.9077
Aptose Biosciences Inc Stock (APTO) Company Profile
Name
Aptose Biosciences Inc
Sector
Industry
Phone
310-849-8060
Address
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
Compare APTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.179 | 3.48M | 0 | -51.21M | -44.62M | -7.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Feb-20-20 | Initiated | Maxim Group | Buy |
| Feb-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | Piper Sandler | Overweight |
| Mar-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Nov-16-18 | Initiated | B. Riley FBR | Buy |
| Dec-13-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-07-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-08-17 | Initiated | Rodman & Renshaw | Neutral |
View All
Aptose Biosciences Inc Stock (APTO) Latest News
Aptose Biosciences CEO William Rice acquires $20,000 in shares - Investing.com
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering - GlobeNewswire
Aptose Biosciences Boosts Capital with $8M Offering - TipRanks
Aptose Biosciences Completes $8M Public Offering with Insider Participation | APTO Stock News - StockTitan
Form 424B4 Aptose Biosciences Inc. - StreetInsider.com
SEC Form 424B4 filed by Aptose Biosciences Inc. - Quantisnow
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Aptose sets $8 million target in stock and warrant offering By Investing.com - Investing.com South Africa
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views - Benzinga
Aptose sets $8 million target in stock and warrant offering - Investing.com India
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering - GlobeNewswire
Dow Jumps 300 Points; Gap Posts Upbeat Earnings - Benzinga
Aptose Biosciences Inc. - Baystreet.ca
Aptose Biosciences Announces $8 Million Public Offering - TipRanks
Aptose Biosciences Raises $8M in Public Offering with Warrant Package at $0.20 Per Share | APTO Stock News - StockTitan
Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket - Benzinga
Stocks In Play: Aptose Biosciences Inc. - Barchart
Aptose Biosciences stock plunges to 52-week low of $0.33 By Investing.com - Investing.com Canada
Aptose Biosciences stock plunges to 52-week low of $0.33 - Investing.com India
Aptose Initiates TUSCANY Phase 1/2 Study for Newly - GlobeNewswire
Aptose Launches Phase 1/2 Trial Testing Novel AML Triplet Therapy with Tuspetinib | APTO Stock News - StockTitan
ARMISTICE CAPITAL, LLC Increases Stake in Aptose Biosciences Inc - GuruFocus.com
Aptose Biosciences Inc. (APTO) Quarterly 10-Q Report - Quartz
Aptose Biosciences Reports Q3 2024 Financial Highlights - TipRanks
Aptose Reports Results for the Third Quarter 2024 - GlobeNewswire
Aptose Biosciences Cuts Q3 Losses, Secures $10M Loan Amid Nasdaq Challenges | APTO Stock News - StockTitan
Aptose Biosciences Advances AML Triplet Therapy - TipRanks
Hanmi and MEDiC ink cancer biomarker collaboration deal - Pharmaceutical Technology
Aptose Biosciences faces delisting from NASDAQ - Investing.com India
Aptose Biosciences faces delisting from NASDAQ By Investing.com - Investing.com South Africa
Analysts’ New Coverage for September 18th (AINC, AIRI, APTO, ARM, AVGO, BGNE, CAN, CARA, CHH, CLLS) - Defense World
Aptose Biosciences secures shareholder nod for warrant issuance - Investing.com
Aptose Biosciences stock hits 52-week low at $0.34 - Investing.com
Aptose Biosciences Shareholders Endorse Key Resolutions - TipRanks
Aptose Announces Results from Special Meeting of Shareholders - GlobeNewswire
A significant driver of top-line growth: Aptose Biosciences Inc (APTO) - SETE News
Aptose Biosciences Inc Inc. (APTO) Price Performance: A Technical Analysis Perspective - The InvestChronicle
APTO’s earnings forecast for the current quarter - US Post News
Daily Market Movement: Aptose Biosciences Inc (APTO) Sees a 2.19 Increase, Closing at 0.41 - The Dwinnex
Hello Group, Zscaler And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Aptose Biosciences secures funds for AML treatment development - Pharmaceutical Technology
Aptose Biosciences (NASDAQ:APTO) Receives New Coverage from Analysts at StockNews.com - Defense World
Aptose secures $10 million loan for leukemia drug development - Investing.com India
APTOAptose Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Aptose Biosciences Secures Convertible $10M Loan from Hanmi - TipRanks
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib - Yahoo Finance
Aptose Receives $10 Million Through a Facility Agreement - GlobeNewswire
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences stock hits 52-week low at $0.4 amid downturn - Investing.com
APTO’s Market Whiplash: -81.82% YTD Decline, -24.89% Plunge in 30 Days - The InvestChronicle
Market Resilience: Aptose Biosciences Inc (APTO) Finishes Weak at 0.46, Down -4.82 - The Dwinnex
Aptose Biosciences Inc Stock (APTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):